Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
Seres Therapeutics announced three poster presentations at the upcoming 2025 Digestive Disease Week (DDW) Conference in San Diego. The company will showcase new research on live biotherapeutics for treating inflammatory and immune diseases, including ulcerative colitis and Crohn's disease.
The presentations include two new research posters focusing on:
- Characterization of IBD microbiomes to evaluate candidate biomarkers
- Biomarkers of microbiome disruption for patient selection in UC trials
A third poster will present previously disclosed results from the SER-155 Phase 1b study, which demonstrated positive outcomes in promoting intestinal barrier integrity and modulating inflammatory responses. Seres is actively seeking partnerships to advance their biotherapeutics development in inflammatory and immune diseases.
Seres Therapeutics ha annunciato tre presentazioni poster al prossimo Digestive Disease Week (DDW) 2025 che si terrà a San Diego. L'azienda presenterà nuove ricerche sulle bioterapie viventi per il trattamento delle malattie infiammatorie e immunitarie, tra cui colite ulcerosa e morbo di Crohn.
Le presentazioni includono due nuovi poster di ricerca focalizzati su:
- Caratterizzazione dei microbiomi nelle IBD per valutare potenziali biomarcatori
- Biomarcatori di alterazione del microbioma per la selezione dei pazienti negli studi sulla colite ulcerosa
Un terzo poster presenterà i risultati già divulgati dello studio di fase 1b SER-155, che ha evidenziato esiti positivi nel promuovere l'integrità della barriera intestinale e nel modulare le risposte infiammatorie. Seres è attivamente alla ricerca di partnership per avanzare nello sviluppo delle bioterapie nelle malattie infiammatorie e immunitarie.
Seres Therapeutics anunció tres presentaciones en formato póster en la próxima Conferencia Digestive Disease Week (DDW) 2025 en San Diego. La compañía mostrará nuevas investigaciones sobre bioterapéuticos vivos para el tratamiento de enfermedades inflamatorias e inmunitarias, incluyendo colitis ulcerosa y enfermedad de Crohn.
Las presentaciones incluyen dos nuevos pósters de investigación centrados en:
- Caracterización de microbiomas en EII para evaluar biomarcadores candidatos
- Biomarcadores de disrupción del microbioma para la selección de pacientes en ensayos de CU
Un tercer póster presentará resultados previamente divulgados del estudio de fase 1b SER-155, que demostró resultados positivos en la promoción de la integridad de la barrera intestinal y la modulación de respuestas inflamatorias. Seres está buscando activamente asociaciones para avanzar en el desarrollo de sus bioterapéuticos en enfermedades inflamatorias e inmunitarias.
Seres Therapeutics가 다가오는 2025 소화기 질환 주간(DDW) 컨퍼런스에서 세 편의 포스터 발표를 진행할 예정입니다. 이 회사는 궤양성 대장염과 크론병을 포함한 염증 및 면역 질환 치료를 위한 생체 치료제에 관한 새로운 연구를 선보일 것입니다.
발표 내용은 다음 두 가지 새로운 연구 포스터를 포함합니다:
- IBD 마이크로바이옴 특성화 및 후보 바이오마커 평가
- 궤양성 대장염 임상시험 환자 선정을 위한 마이크로바이옴 교란 바이오마커
세 번째 포스터는 장벽 무결성 증진과 염증 반응 조절에 긍정적 결과를 보인 SER-155 1b상 연구의 이전 공개 결과를 발표할 예정입니다. Seres는 염증 및 면역 질환 생체 치료제 개발을 위해 적극적으로 파트너십을 모색하고 있습니다.
Seres Therapeutics a annoncé trois présentations sous forme de posters lors de la prochaine Digestive Disease Week (DDW) 2025 à San Diego. La société présentera de nouvelles recherches sur les biothérapies vivantes pour le traitement des maladies inflammatoires et immunitaires, notamment la colite ulcéreuse et la maladie de Crohn.
Les présentations comprennent deux nouveaux posters de recherche axés sur :
- La caractérisation des microbiomes dans les MICI pour évaluer les biomarqueurs candidats
- Les biomarqueurs de perturbation du microbiome pour la sélection des patients dans les essais sur la CU
Un troisième poster présentera des résultats déjà publiés de l'étude de phase 1b SER-155, qui a démontré des résultats positifs en favorisant l'intégrité de la barrière intestinale et en modulant les réponses inflammatoires. Seres recherche activement des partenariats pour faire avancer le développement de ses biothérapies dans les maladies inflammatoires et immunitaires.
Seres Therapeutics gab drei Posterpräsentationen auf der bevorstehenden Digestive Disease Week (DDW) 2025 in San Diego bekannt. Das Unternehmen wird neue Forschungsergebnisse zu lebenden Biotherapeutika zur Behandlung von Entzündungs- und Immunerkrankungen, einschließlich Colitis ulcerosa und Morbus Crohn, vorstellen.
Die Präsentationen umfassen zwei neue Forschungsplakate mit Fokus auf:
- Charakterisierung von IBD-Mikrobiomen zur Bewertung potenzieller Biomarker
- Biomarker für Mikrobiomstörungen zur Patientenauswahl in UC-Studien
Ein drittes Poster wird bereits veröffentlichte Ergebnisse der SER-155 Phase-1b-Studie präsentieren, die positive Effekte bei der Förderung der Darmbarriereintegrität und der Modulation entzündlicher Reaktionen zeigte. Seres sucht aktiv Partnerschaften, um die Entwicklung ihrer Biotherapeutika bei entzündlichen und immunologischen Erkrankungen voranzutreiben.
- Advancing development of SER-155 with positive Phase 1b biomarker data supporting therapeutic mechanisms
- Active pursuit of partnership opportunities for inflammatory and immune disease programs
- Multiple data presentations at major industry conference (DDW) showing scientific progress
- Still in early clinical development phases, requiring further studies
- Dependence on potential partnerships to advance inflammatory and immune disease programs
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA.
Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases, including ulcerative colitis and Crohn’s disease.
Seres is currently seeking partnership opportunities to advance the development of its biotherapeutics in inflammatory and immune diseases.
Presentation Details - New Research
Title: Characterization of IBD microbiomes in Models of Microbiome Disruption and Inflammation to Evaluate Candidate Biomarkers for Patient Selection
Abstract Number: Sa1770
Presenter: Nicholas Beauchemin, Principal Scientist, R&D
Date & Time: May 3, 2025 from 12:30 PM to 1:30 PM
Title: Candidate Biomarkers of Microbiome Disruption for Patient Selection or Stratification in Clinical Trials of Microbiome Therapeutics in Ulcerative Colitis (UC)
Abstract Number: Sa1767
Presenter: Nicholas Beauchemin, Principal Scientist, R&D
Date & Time: May 3, 2025 from 12:30 PM to 1:30 PM
Presentation Details - Encore of Previously Disclosed Results
Title: Pharmacokinetic (PK) and pharmacodynamic (PD) results from a randomized, double-blind, placebo-controlled Cohort 2 of a Phase 1b study of an investigational, oral, live biotherapeutic, SER-155, in adults undergoing allo-HCT
Abstract Number: Su2009
Presenter: Christopher Ford, SVP, R&D
Date & Time: May 4, 2025 from 12:30 PM to 1:30 PM
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases nearly 6,000 abstracts and over 1,000 invited talks on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
What research will Seres Therapeutics (MCRB) present at DDW 2025?
What are the key findings from Seres Therapeutics' (MCRB) SER-155 Phase 1b study?
What diseases is Seres Therapeutics (MCRB) targeting with their live biotherapeutics?
What are the presentation times for Seres Therapeutics (MCRB) at DDW 2025?
Is Seres Therapeutics (MCRB) seeking partnerships for their biotherapeutics program?
